Kyverna Moves Closer to First Autoimmune CAR-T Approval

Autolus Reports Encouraging CAR-T Data in Severe Lupus

FDA Signals Support for Autoimmune CAR-T Development

In Vivo CAR-T Shows Promise as Next-Generation Cell Therapy

CASTLE Trial Highlights Broad Potential Across Autoimmune Diseases

Novartis & Bristol Myers Squibb Pause Autoimmune CAR-T Trials Following Safety Reviews

Fred Aslan

Fred Aslan

President & Chief Executive Officer Artiva Biotherapeutics, Inc

Seminars

Thursday 3rd December 2026

Chair’s Closing Remarks & End of Conference

4:00 pm

Fred Aslan - CTx Autoimmune

View all Speakers

View Event Brochure